In a patient with persistent painful urticarial lesions lasting >24 hours, resistant to omalizumab (Xolair), prednisone, dupilumab (Dupixent) and over‑the‑counter antihistamines, with bruising, hyperpigmentation, joint pain, angioedema, elevated C‑reactive protein and erythrocyte sedimentation rate, neutrophilia, exhaustion and excessive sweating, what diagnostic work‑up and treatment plan are recommended?

This is Urticarial Vasculitis Until Proven Otherwise—Obtain a Skin Biopsy Immediately

The combination of wheals lasting >24 hours, pain/burning quality, bruising, hyperpigmentation, joint pain, elevated inflammatory markers (CRP 3.5, ESR 19), and resistance to standard urticaria therapies strongly suggests urticarial vasculitis rather than chronic spontaneous urticaria. You need a skin biopsy of an active lesion (ideally <24 hours old) to look for leukocytoclastic vasculitis with neutrophil-rich infiltrates and vessel wall damage 1.

Immediate Diagnostic Work-Up

Critical distinguishing features already present:

• Wheal duration >24 hours (classic for UV vs typical CSU where wheals last <24 hours)
• Pain/burning rather than pure pruritus
• Post-inflammatory changes (bruising, hyperpigmentation)—typical urticaria resolves without trace
• Systemic symptoms: joint pain, exhaustion, excessive sweating
• Elevated acute phase reactants (CRP, ESR)
• Treatment resistance to mast cell-directed therapies

Required laboratory evaluation 1:

• Complement levels: C3, C4, CH50 (to distinguish normocomplementemic from hypocomplementemic UV—the latter suggests systemic disease)
• Serum protein electrophoresis (SPEP) to screen for paraproteinemia/monoclonal gammopathy
• ANA, anti-dsDNA, RF if complement is low (evaluate for SLE or other connective tissue disease)
• Hepatitis B and C serology (associated with cryoglobulinemia/vasculitis)
• Urinalysis (check for proteinuria/hematuria suggesting renal involvement)

Consider autoinflammatory syndromes given the constellation of fever-equivalent symptoms (exhaustion, sweating), joint pain, and elevated inflammatory markers 1:

• Schnitzler syndrome (especially if paraproteinemia found—typically IgM monoclonal gammopathy)
• Adult-onset Still's disease
• These conditions respond to IL-1 blockade, not antihistamines or anti-IgE therapy

Why Standard Urticaria Treatments Failed

Your patient's resistance to omalizumab, dupilumab, antihistamines, and even prednisone makes perfect sense if this is urticarial vasculitis rather than CSU:

• Omalizumab targets IgE-mediated mast cell activation—UV is immune complex-mediated vasculitis, not primarily mast cell-driven 2
• Dupilumab blocks IL-4/IL-13—effective in type 2 inflammation but UV involves neutrophilic inflammation 3
• Antihistamines block histamine receptors—inadequate when the primary pathology is vessel wall inflammation
• Prednisone resistance at typical doses suggests more aggressive immunosuppression is needed

Treatment Algorithm Based on Biopsy Results

If Biopsy Confirms Urticarial Vasculitis:

For normocomplementemic UV (normal C3/C4):

1. First-line: Continue or optimize omalizumab (300 mg every 2-4 weeks) as recent evidence shows 94% complete remission in normocomplementemic UV 4. The key distinction: your patient may need higher frequency dosing or longer duration (mean treatment 14.8 months in successful cases) 4

2. Second-line if omalizumab inadequate: Add or switch to JAK inhibitors

   • Upadacitinib 30 mg daily showed dramatic improvement in refractory UV within one month when combined with omalizumab 5
   • This addresses the neutrophilic inflammation that omalizumab alone cannot control

3. Alternative: Traditional immunosuppression

   • Dapsone 50-200 mg daily (check G6PD first)
   • Colchicine 0.6 mg twice daily
   • Hydroxychloroquine 200-400 mg daily
   • Mycophenolate mofetil or cyclosporine for refractory cases

For hypocomplementemic UV (low C3/C4):

• This suggests systemic disease requiring rheumatology co-management
• Higher-dose systemic corticosteroids (prednisone 0.5-1 mg/kg)
• Steroid-sparing agents: mycophenolate, azathioprine, or cyclophosphamide
• Screen aggressively for organ involvement (renal, pulmonary, ocular)

If Autoinflammatory Syndrome Suspected:

Schnitzler syndrome (if monoclonal gammopathy present):

• IL-1 blockade: Anakinra 100 mg daily subcutaneous or canakinumab
• Dramatic response typically within days to weeks
• This explains resistance to all mast cell-targeted therapies

Critical Management Pitfalls

Do not continue escalating antihistamines or repeat omalizumab without biopsy confirmation—you're treating the wrong disease mechanism. The 2022 international guidelines explicitly state that wheals lasting >24 hours should trigger evaluation for urticarial vasculitis 1.

Do not dismiss the neutrophilia (78.1%, absolute 7.9)—this supports neutrophilic inflammation consistent with vasculitis rather than eosinophilic/type 2 inflammation.

The angioedema component requires additional consideration: if complement levels are low, also evaluate for acquired angioedema (C1-INH levels/function, C1q, anti-C1-INH antibodies) 1.

Immediate Next Steps

1. Skin biopsy of lesional skin <24 hours old (looking for leukocytoclastic vasculitis, neutrophil-rich infiltrates, fibrinoid deposits)
2. Complete laboratory panel as outlined above
3. If biopsy confirms UV and complement normal: Optimize omalizumab dosing frequency or add upadacitinib 30 mg daily 5, 4
4. If Schnitzler syndrome: Switch to IL-1 blockade
5. Rheumatology referral for co-management given systemic features

The exhaustion and excessive sweating are not incidental—these systemic symptoms combined with joint pain and elevated inflammatory markers indicate this is beyond simple chronic urticaria and requires aggressive investigation for underlying systemic disease 1.